Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine versus pyronaridine-artesunate for uncomplicated falciparum malaria in Upper Myanmar
ACTRN12618001952235Phase 2Completed
- Sponsor
- WHO country office
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of artemether, lumefantrine, pyronaridine and artesunate in malaria and Malaria (2 arms), sponsored by WHO country office. Primary endpoint: Adequate Clinical and Parasitological Response (ACPR). Started Aug 2017; status: completed.
02
Drugs
artemetherlumefantrinepyronaridineartesunate
03
Conditions
malariaMalaria
Beyond the preview
Go deeper on ACTRN12618001952235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001952235.